Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
NeuroSense Therapeutics Ltd. (NRSN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
1Distinct source URLs
3High confidence
0.736Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NeuroSense Therapeutics Ltd. Suppliers
No suppliers on recordNeuroSense Therapeutics Ltd. has not yet been matched to upstream suppliers in our database, or is still being processed.
NeuroSense Therapeutics Ltd. Customers
Ticker
Name
Confidence
Evidence
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRSN graph: ct to the risks associated with preclinical development, including the risks associated with: ● generating adequate …
SNYNF
Sanofi
72%
ct to the risks associated with preclinical development, including the risks associated with: ● generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support …
COGENCY-GLOBAL-INC
COGENCY-GLOBAL-INC
62%
rule were to go into effect and we are unable to maintain our market value of listed securities above $5 million, we would become subject to immediate suspension and delisting. If our ordinary shares…
COORDINATION-GROUP
COORDINATION-GROUP
62%
ilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to …
HEALTH-RESOURCES
HEALTH-RESOURCES
62%
ficate, the requirements mentioned in the registration files and after the packaging, labeling and leaflets for both physicians and consumers have been approved. In addition, the following Pharmaceut…
PASSIVE-FOREIGN-INVESTMENT-COMPANY
PASSIVE-FOREIGN-INVESTMENT-COMPANY
62%
rule were to go into effect and we are unable to maintain our market value of listed securities above $5 million, we would become subject to immediate suspension and delisting. If our ordinary shares…
NeuroSense Therapeutics Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
NRSN-DEBT-11368
Warrants outstanding: 3000000
90%
xbrl warrant detail from xbrl 2025-12-31.
NRSN-DEBT
Debt stack $170,000
90%
Market cache reports total debt of $170,000.
NeuroSense Therapeutics Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NeuroSense Therapeutics Ltd..
NeuroSense Therapeutics Ltd. Ownership
Holder
Name
Confidence
Evidence
NRSN-OWNER-YORKVILLE-ADVISORS-GLOBAL-LP
Yorkville Advisors Global, LP
90%
13F overlay lists Yorkville Advisors Global, LP as top holder; 14 tracked holders.
